Lexington, MA, United States
Lexington, MA, United States

Time filter

Source Type

Patent
Concert Pharmaceuticals | Date: 2016-10-12

This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.


Patent
Concert Pharmaceuticals | Date: 2016-03-11

This disclosure relates to novel morphinan compounds and their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a _(1 )receptor agonist that also has NMDA antagonist activity.


Patent
Concert Pharmaceuticals | Date: 2017-03-22

This invention relates to novel tetrahydronaphthalene derivatives, and pharmaceutically acceptable salts thereof according to the following formula C, in one embodiment, as described herein. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a selective T-type calcium channel blocker.


Patent
Concert Pharmaceuticals | Date: 2017-02-22

The present invention relates to a novel method of treating hyperglycemia in a patient with poor glycemic control. The method comprises administering to the patient an effective amount of a compound described herein.


Patent
Concert Pharmaceuticals | Date: 2016-11-22

This invention relates to compounds of Formula I: and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a CFTR potentiator.


Patent
Concert Pharmaceuticals | Date: 2016-11-30

The present invention in one embodiment provides a compound of Formula I, or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.


Patent
Concert Pharmaceuticals | Date: 2016-07-27

The present invention in one embodiment provides a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula I are as defined in the specification.


Patent
Concert Pharmaceuticals | Date: 2016-01-06

This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.


Provided herein are compositions comprising a dextromethorphan analog according to Formula II or a pharmaceutically acceptable salt thereof, and a co-agent which is norepinephrine-dopamine reuptake inhibitor (NDRI) or a pharmaceutically acceptable salt thereof. The compositions are use ful in the treatment of pseudobulbar affect, neuropathic pain, neurological disorders, brain injuries and the like:


Patent
Concert Pharmaceuticals | Date: 2016-05-06

This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a al receptor agonist that also has NMDA antagonist activity.

Loading Concert Pharmaceuticals collaborators
Loading Concert Pharmaceuticals collaborators